Primary carnitine deficiency is a disorder of fatty acid oxidation caused by mutations in the Na ؉ -dependent carnitine/organic cation transporter OCTN2. Studies with tyrosyl group-modifying reagents support the involvement of tyrosine residues in Na ؉ binding by sodium-coupled transporters. Here we report two new patients with carnitine deficiency caused by mutations affecting tyrosyl residues (Y447C and Y449D) close to a residue (Glu-452) previously shown to affect sodium stimulation of carnitine transport. Kinetic analysis indicated that the Y449D substitution, when expressed in Chinese hamster ovary cells, increased the concentration of sodium required to half-maximally stimulate carnitine transport from 14.8 ؎ 1.8 to 34.9 ؎ 5.8 mM (p < 0.05), whereas Y447C completely abolished carnitine transport. Substitution of these tyrosine residues with phenylalanine restored normal carnitine transport in Y449F but resulted in markedly impaired carnitine transport by Y447F. This was associated with an increase in the concentration of sodium required to halfmaximally stimulate carnitine transport to 57.8 ؎ 7.4 mM (p < 0.01 versus normal OCTN2). The Y447F and Y449D mutant transporters retained their ability to transport the organic cation tetraethylammonium indicating that their effect on carnitine transport was specific and likely associated with the impaired sodium stimulation of carnitine transport. By contrast, the Y447C natural mutation abolished the transport of organic cations in addition to carnitine. Confocal microscopy of OCTN2 transporters tagged with green fluorescent protein indicated that the Y447C mutant transporters failed to reach the plasma membrane, whereas Y447F, Y449D, and Y449F had normal membrane localization. These natural mutations identify tyrosine residues possibly involved in coupling the sodium electrochemical gradient to transmembrane solute transfer in the sodium-dependent co-transporter OCTN2.
Primary carnitine deficiency (Online Mendelian Inheritance in Man number 212140) is a recessively inherited disorder of fatty acid oxidation due to defective carnitine transport (1) . Carnitine is essential for the transfer of long-chain fatty acids from the cytosol to mitochondria for subsequent ␤-oxidation, and the lack of carnitine impairs the ability to use fat as fuel during periods of fasting or stress. This can result in hypoketotic hypoglycemia, Reye syndrome, and sudden infant death in younger children or in skeletal or cardiac myopathy with insidious onset later in life (1) . These clinical manifestations can be prevented by lifelong pharmacological carnitine treatment (1) .
The gene for primary carnitine deficiency, SLC22A5, encodes the carnitine transporter OCTN2 (2, 3) , and heterogeneous mutations have been identified in affected patients (reviewed in Refs. 4 and 5) . OCTN2 is a novel organic cation transporter and operates a sodium-dependent transport of carnitine (3, 5, 6 ) and a sodium-independent uptake of organic cations (6 -9) . The molecular bases of its multispecificity are not known, and there is no information on the domains involved in recognizing carnitine, organic cations, or sodium.
The study of natural mutations in this transporter is uncovering domains potentially important for function. The P478L substitution identified in a patient with primary carnitine deficiency markedly impaired carnitine transport but retained normal transport of tetraethylammonium (TEA), 1 a prototypic organic cation (8) . Because the transport of carnitine is sodiumdependent whereas that of organic cations is not, it was thought that this mutation could affect the sodium stimulation of carnitine transport (8) . However, the kinetics of sodium stimulation of carnitine transport were comparable between the normal and the mutant transporter, negating this hypothesis (8) . Similar properties were observed with another natural mutation, S467C, located close to P478L (9) , leading to the hypothesis that transmembrane domain 11, which contains both substitutions, is involved in the recognition of the negative charge of the zwitterion carnitine, whereas the positive charge of organic cations is recognized by another portion of the transporter (9) . The S467C mutation, as P478L, did not affect sensitivity of the residual carnitine transport to sodium, indicating that it was not involved in the sodium stimulation of carnitine transport (9) .
By contrast, the study of a mutation identified in a patient with cardiomyopathy (10) has identified a domain located around glutamic acid 452 of OCTN2, which is important for transmembrane sodium/solute transfer (11) . In this case, the mutant transporter retained a normal membrane localization and a normal affinity toward carnitine (10, 11) . However, the affinity of the E452K mutant transporter toward carnitine was significantly decreased with an increase in K Na from 12 to 187 mM (11) . Because the K m toward carnitine changed similarly in the normal and E452K mutant transporters as the concentration of extracellular sodium was decreased, it was concluded that the E452K mutation was not located close to the carnitine binding site (11) . In fact, the current modeling of the OCTN2 carnitine/organic cation transporter places the E452K mutation in an intracellular loop located between transmembrane domains 10 and 11 (2, 3) , an unlikely carnitine binding site. It is not known whether the E452K substitution also impairs the transport of organic cations (11) .
Based on studies with tyrosyl group-specific reagents, it is believed that tyrosyl residues are potential sodium binding sites in sodium/substrate cotransporters (12) (13) (14) (15) . Site-directed mutagenesis of selected tyrosine residues in the OCTN2 transporter, however, failed to identify residues involved in sodium stimulation of carnitine transport (8) Substitution with phenylalanine of tyrosines 239, 251, 426, 479, 482, and 492, all located in predicted extracellular or transmembrane domains, had no effect on carnitine or organic cation transport (8) . Substitution of tyrosines 358 and 486 impaired both carnitine and organic cation transport, although the underlying mechanism was not defined (8) . Finally, Y211F impaired carnitine but not organic cation transport. However, as in the case of P478L, there was no difference in the kinetics of sodium stimulation of carnitine transport in the Y211F mutant (8) .
In this paper, we identified mutations in the tyrosine residues associated with defective carnitine transport in cells from patients with abnormal fatty acid oxidation. These tyrosine residues were located close to the E452K mutation previously found to affect the sodium stimulation of carnitine transport. Kinetic studies confirmed that these tyrosines affected sodium stimulation of carnitine transport.
EXPERIMENTAL PROCEDURES
Patients-Patient AL-1 is a 5-year-old Saudi female with a normal birth history and development who presented at 22 months of age with bronchiolitis. A chest x-ray performed at that time demonstrated cardiomegaly. An echocardiography indicated left ventricular hypertrophy with poor contractility. A metabolic evaluation demonstrated low plasma carnitine levels. She was started on carnitine with good improvement of the ventricular function. The parents of this child are first cousins and have six other healthy children.
Patient 8 presented with a fever at 3 months of age. He suffered a cardiac arrest during a lumbar puncture performed to exclude sepsis (see patient 8 in Ref. 16 ). At autopsy, liver steatosis was identified in addition to lung colonization by Gram-positive bacteria. This patient was heterozygous for a carnitine transport defect and variations in other genes. Synergistic heterozygosity between genes encoding different enzymes/transporters in the carnitine cycle and fatty acid oxidation was proposed as the cause for defective fatty acid oxidation by his fibroblasts and for his clinical presentation (16) .
DNA Analysis-Institutional Review Board approval and informed consent from the parents of the patients was obtained for DNA studies. Genomic DNA was extracted either from fibroblasts or peripheral blood by standard methods and amplified using PCR and primers flanking each of the 10 exons of the SLC22A5 gene (4, 5, 17) . PCR products were visualized by agarose gel electrophoresis, purified by a Qiagen column, and sequenced directly without subcloning using an ABI automated DNA sequencer (4, 5, 17) . Mutations were confirmed by sequencing in both directions in two independent PCR products. The Y449D mutation abolished a RsaI restriction site, and restriction analysis was used to confirm heterozygosity for this mutation.
Cell Culture and Carnitine Transport-Human fibroblasts were obtained from skin biopsies of patients with carnitine deficiency after informed consent. Fibroblasts were grown in Dulbecco's modified Eagle's medium supplemented with 15% fetal bovine serum. L-[
3 H]Methylcarnitine (81 Ci/mmol, Amersham Biosciences) transport in human fibroblasts was measured as previously described (10) .
Chinese hamster ovary (CHO) cells were grown in Ham's F12 medium supplemented with 6% fetal bovine serum. Carnitine and TEA transport were measured at 37°C with the cluster tray method as described previously (11, 17) . Cells were grown to confluence in 24-well plates (Costar) and depleted of intracellular amino acids by incubation for 90 min in Earle's balanced salt solution containing 5.5 mM D-glucose and supplemented with 0.1% bovine serum albumin. Carnitine (0.5 M, 0.5 Ci/ml) or TEA (10 M, 0.25 Ci/ml) was then added to the cells for 20 min. Nonsaturable carnitine and TEA transport was measured in the presence of 2 or 20 mM cold substrate, respectively. The transport reaction was stopped by rapidly washing the cells 4 times with ice-cold 0.1 M MgCl 2 . Intracellular carnitine and TEA were extracted from the cells with 0.5 ml of ice-cold ethanol and added to 5 ml of scintillation fluid for counting. Intracellular carnitine and TEA were normalized for the protein content of each well and intracellular water content and were expressed as nanomoles per ml of cell water (11) . Saturable carnitine and TEA transport was calculated by subtracting transport in the presence of excess cold substrate from total transport, and values are reported as means Ϯ S.E. of 3-6 independent determinations. Initial experiments on CHO cells either transfected or not with OCTN2 indicated that carnitine (0.5 M) accumulation was linear up to 30 min, whereas TEA (1 M) accumulation was linear up to 90 min (not shown).
Kinetic constants for carnitine (0.5-100 M) transport were determined by nonlinear regression analysis according to a Michaelis-Menten equation (10, 11) . Nonsaturable carnitine transport, measured in the presence of 2 mM carnitine, was subtracted from total transport to obtain saturable carnitine transport prior to nonlinear regression analysis (11) . Carnitine transport in the absence of sodium was measured substituting methylglucamine for sodium, so that the sum of methylglucamine and sodium remained constant at 150 mM (11, 18) . Nonlinear parameters are expressed in the text and figures as means Ϯ S.D.
In previous studies, we used multiple carnitine concentrations to define the K m of OCTN2 toward sodium (K Na ) (11, 18) . However, we noted that the value obtained from the intercept of multiple regressions was identical to the value obtained at the lowest concentration of carnitine (0.5 M, Refs. 10 and 18). This is because, in a random bireactant system such as the carnitine/sodium cotransporter, the apparent K m toward the cosubstrate (K Na ) approaches the true K m (K Na ) as the concentration of the substrate (carnitine) decreases to near zero (19) . Because our previous studies (11, 18) indicated experimentally that a concentration of 0.5 M carnitine provided values of apparent K Na indistinguishable from those calculated from the intersection of multiple curves, in this study we used an even lower concentration of carnitine (0.1 M) to obtain an apparent K Na that closely approaches true K Na . As shown in the results below, the values obtained with this system are similar or identical to those previously published in these cells (11) and other cells expressing the OCTN2 transporter (18) .
OCTN2 Expression Vectors-The vector containing the OCTN2 cDNA fused in-frame with the green fluorescent protein was described previously (11) . This plasmid and the corresponding mutants were transfected into CHO cells by LipofectAMINE according to the manufacturer's instructions (Invitrogen). Cells were selected with 0.8 mg/ml G418 (Invitrogen) for 2 weeks, and a mass culture comprising several independent clones of transfected cells was isolated.
Mutant OCTN2 cDNAs were created by site-directed mutagenesis using the QuikChange system (Stratagene) following the manufacturer's instructions. The final plasmids were sequenced to confirm the presence of the mutation and the absence of PCR artifacts. The plasmids obtained were then transfected into CHO cells as above.
Expression of the recombinant plasmids was monitored by Northern blot analysis (4, 11) . Briefly, total RNA extracted from transfected cells was separated by formaldehyde-agarose gel electrophoresis, blotted to nylon, and hybridized in high stringency conditions to the full-length OCTN2 cDNA labeled with [␣-32 P]dCTP (4, 11) . Bands were then visualized by autoradiography. The intensity of the bands was quantified by the program NIH Image and the subtraction of lane-specific background. OCTN2 mRNA was then normalized to the intensity of the 28 S RNA visible by ethidium bromide staining.
Confocal Microscopy-Subcellular distribution of normal and mutant OCTN2 carnitine transporters conjugated with green fluorescent protein was analyzed with confocal microscopy (Olympus FVX laser scanning confocal IX70 microscope using a 60ϫ 1.4NA PLANAPO oil objective). Cells were seeded on glass bottom (no. 0 cover glass) microwell dishes (P35G-0-14-C, MatTek Corporation, Ashland, MA), covered with medium, and evaluated in vivo. Images of the cells were obtained at 1 m sections. Multiple cells were scanned, and the ones shown in the figures are representative of the fields observed. Contrast microscopy was used on the same cells to define cell borders and intracellular structures. The two images were then digitally superimposed using Adobe PhotoShop.
RESULTS

Identification of Mutations in Patients with
Carnitine Deficiency-To confirm a defect in the carnitine transporter, carnitine transport was measured in fibroblasts obtained from patients AL-1 and 8 (Fig. 1A) . Carnitine transport was negligible in fibroblasts from patient AL-1 confirming a diagnosis of primary carnitine deficiency. By contrast, carnitine transport was reduced to about 50% of normal in fibroblasts from patient 8 and in the range measured in fibroblasts from known heterozygotes for primary carnitine deficiency, consistent with heterozygosity for a mutation in the carnitine transporter gene (SLC22A5).
To identify the causative mutations, the 10 exons of the SLC22A5 gene were amplified by PCR and sequenced. Two significant variations were identified in DNA from the patients. Patient AL-1 was homozygous (and both parents were heterozygous, not shown) for a single bp change converting the codon for tyrosine 447 (TAC) to cysteine (TGC, Y447C) (Fig.  1B) . Patient 8 was heterozygous for a single bp change converting the codon for tyrosine 449 (TAC) to aspartate (GAC, Y449D) (Fig. 1C) . This mutation removed a RsaI restriction site from exon 8 (Fig. 1C) . PCR amplification of exon 8 and digestion with RsaI confirmed that this patient was heterozygous for the Y449D mutation and had both the normal 151-and 112-bp DNA fragments and the undigested 263-bp DNA fragments (Fig. 1D) .
Expression of Mutant Transporters in CHO Cells-To confirm the causative role of the mutations identified, the Y447C and Y449D mutations were created in the OCTN2 cDNA and stably expressed in CHO cells ( Fig. 2A) . Carnitine transport was completely abolished by the Y447C substitution and was reduced to about 10% of the normal OCTN2 in cells expressing the Y449D, confirming a causative role of these mutations in reducing carnitine transport in the fibroblasts of the patients.
To verify the expression of normal and mutant plasmids in CHO cells, the levels of OCTN2 mRNA were measured by Northern blot analysis (Fig. 3 ). All transfected cells had a visible band size of about 3500 nucleotides corresponding to the OCTN2 mRNA. Y447C and Y449D had OCTN2 mRNA levels that were reduced compared with the cells expressing the wild type OCTN2 plasmid. After normalization for OCTN2 mRNA levels, carnitine transport remained absent in cells expressing Y447C-OCTN2 and was reduced to about 18% of wild type OCTN2 in cells expressing Y449D-OCTN2.
Role of Tyrosines 447, 449, and 454 of OCTN2 in Carnitine Transport-Based on the current model of the carnitine transporter OCTN2 (2, 3) and the similarity with other SLC22 drug transporters (20) , both tyrosine 447 and 449 that mutated in our patients were located in an intracellular loop between transmembrane domains 10 and 11 (Fig. 4) . These substitutions were in the same domain containing the E452K mutation previously identified in another patient with primary carnitine deficiency and shown to impair coupling of the sodium electrochemical gradient to carnitine transfer (10, 11) . A third tyrosine (454) was located in the same domain.
Because tyrosine residues were previously proposed (12-15) to play a major role in sodium binding in sodium dependent transporters, we wanted to test the sodium-dependence of the mutant transporters. However, the Y447C mutation fully abolished carnitine transport. Therefore, no analysis was possible for this mutant. For this reason, additional mutants in which tyrosine was substituted by the more conserved phenylalanine were obtained, and tyrosine 454 was also included in this study for completeness. As shown in Fig. 2 , Y447F had significantly decreased carnitine transport, whereas Y449F and Y454F retained normal carnitine transport. After normalization for mRNA levels (Fig. 3) , cells expressing the Y449F and Y454F mutant OCTN2 transporters actually had a 2-3-fold increase in carnitine transport activity as compared with wild type OCTN2. By contrast, the activity of Y447F transporters remained markedly decreased to about 12% of the value observed in wild type OCTN2 transporters after correction for transcript levels.
To determine the mechanisms by which Y449D and Y447F decreased carnitine transport, we measured the kinetic constant of normal and mutant OCTN2 toward carnitine (Fig. 5) . We also re-evaluated the E452K-mutant carnitine transporter previously shown to require increased concentration of sodium to stimulate carnitine transport (11) . As shown in Fig. 5,  Y449D , Y449F, E452K, and Y454F retained a normal affinity toward carnitine. A significant decrease in V max was measured in Y447F, Y449D, and E452K. Y447F had a mild, but significant, increase in the K m toward carnitine to 9.3 Ϯ 1.2 M (normal is 3.2 Ϯ 0.9 M). More differences were observed when the sodium stimulation of carnitine transport was measured (Fig. 6) . Half-maximal stimulation of carnitine transport was seen at a sodium concentration of 14.9 Ϯ 1.8 mM in the normal OCTN2, a value very similar to that previously measured in the same cells and in human fibroblasts (11, 18) . Similar values (15.7 Ϯ 3.7 and 12.2 Ϯ 1.5 mM) were measured in cells expressing Y449F and Y454F that do not impair carnitine transport. The E452K-mutant transporter had a significant increase in the concentration of sodium required for half-maximal stimulation of carnitine transport (125 Ϯ 29 mM, p Ͻ 0.01 versus OCTN2 using 99% confidence intervals) as previously reported (11) . The concentration of sodium at which half-maximal stimulation of carnitine transport was observed was also increased with Y447F (57.8 Ϯ 7.4 mM, p Ͻ 0.01 versus OCTN2) and with Y449D (34.9 Ϯ 5.8 mM, p Ͻ 0.05 versus OCTN2).
Transport of the Organic Cation Tetraethylammonium by Normal and Mutant OCTN2-The carnitine transporter operates a sodium-dependent transport of carnitine and a sodiumindependent transport of organic cations (3, 6 -9) . Other mutations in OCTN2 impair carnitine transport without affecting TEA transport (8, 9) . These mutations, however, do not affect sensitivity to sodium stimulation (8, 9) . If the Y449D and Y447F substitution prevalently affected sodium stimulation of carnitine transport they could have retained normal cation transport activity. To test this hypothesis, the transport of the prototypic organic cation TEA was measured in CHO cells expressing normal and mutant OCTN2 transporters (Fig. 2B) . OCTN2 stimulated TEA transport above the level measured in untransfected cells. The Y447C substitution abolished the increase in TEA transport. The other substitutions increased TEA transport above the level measured in untransfected CHO cells significantly (p Ͻ 0.01, using analysis of variance) with Y449F actually increasing it above the level measured with the wild type OCTN2.
Subcellular Localization of Mutant Transporters-Because Y447C abolished both carnitine and TEA transport, we wondered whether it affected the maturation of the transporter to the plasma membrane. Because our transporters were tagged with the green fluorescent protein (GFP) (11), we visualized them by confocal microscopy. As shown in Fig. 7 , the wild type OCTN2 transporter was distributed along the cell membrane when the signal from GFP (Fig. 7A) was superimposed onto the cells visualized by contrast microscopy (Fig. 7, B and C) . By contrast, Y447C transporters had a diffuse cytoplasmic distribution with more signal in the perinuclear region (Fig. 7, D, E,  and F) . There was no enhancement of the fluorescence in the region corresponding to the cell membrane in CHO cells expressing the Y447C-mutant OCTN2 transporter. This lack of transporters on the plasma membrane can explain the complete lack of activity, measured either as carnitine or TEA transport, by the Y447C-mutant transporter.
To exclude the possibility that other mutants impaired carnitine transport by this mechanism, their subcellular distribution was also analyzed. Y447F, Y449D, Y449F, and Y454F tagged with the green fluorescent protein reached the plasma membrane and had a distribution comparable with that of wild type OCTN2 (Fig. 8) .
DISCUSSION
The OCTN2 carnitine/organic cation transporter is a multispecific solute carrier that operates a sodium-dependent transport of carnitine (3, 6, 7) and a sodium-independent uptake of organic cations (2, 3, 6 -9) . The domains involved in recognizing carnitine, organic cations, or sodium are not known.
Tyrosyl residues are potential sodium binding sites in sodium/substrate cotransporters (12) (13) (14) (15) . OCTN2 contains 20 tyrosine residues of 557 amino acids (2, 3) . Of these tyrosine residues, nine (211, 239, 251, 358, 426, 479, 482, 486, and 492) are located in or near the outer aspect of the predicted transmembrane domains. Substitution of all of these tyrosines with phenylalanine did not affect the sensitivity of carnitine transport to sodium stimulation (8) . Of the remaining 11 tyrosine residues, 2 (84 and 124) are located in predicted extracellular loops, 4 are located in or near predicted transmembrane domains (243, 387, 401, and 425), and 5 are located in predicted intracellular loops (4, 396, 447, 449, and 454). Interestingly, three tyrosines (447, 449, and 454) of this latter group are all in the same intracellular loop between transmembrane domains 10 and 11. In a patient with primary carnitine deficiency, we had previously identified a mutation (E452K) located in this region that increased the concentration of sodium to half-maximally stimulate carnitine transport (11). Here we report two additional natural mutations in two of the three tyrosines located in the intracellular loop comprising E452K (Y447C and Y449D, Fig. 1 ).
Given our previous results with the E452K mutation and the possible involvement of tyrosine residues in sodium binding, we analyzed the role of these tyrosines on the sodium stimulation of carnitine transport. The natural mutations Y447C and Y449D impaired carnitine transport when expressed in CHO cells (Fig. 2) . Y447C completely abolished carnitine transport, whereas Y449D retained residual carnitine transport activity. When tyrosine residues 447, 449, and 454 were substituted by phenylalanine residues, only the substitution of residue 447 impaired carnitine transport (Fig. 2) . Decreased carnitine transport by Y447F and Y449D was associated with a decreased V max but a normal or near normal K m for carnitine uptake (Fig. 5) . The kinetics of sodium stimulation of carnitine transport indicated that both the Y447F and the Y449D substitutions increased the concentration of sodium required to half-maximally stimulate carnitine transport from 14.9 Ϯ 1.8 to 57.8 Ϯ 7.4 mM and 34.9 Ϯ 5.8 mM, respectively (Fig. 6) . The E452K substitution also increased the concentration of sodium required to half-maximally stimulate carnitine transport to 125 Ϯ 29 mM (Fig. 6) , as previously reported (11) .
If the Y447F, Y449D, and E452K mutations affected only sodium stimulation of carnitine transport, the uptake of organic cations should remain unaffected. This was indeed the case, and the three substitutions (Y447F, Y449D, and E452K) retained the normal transport of the prototypic cation tetraethylammonium (Fig. 2B) . Normal transport of organic cations has been found with two other natural mutations, P478L and S467C (8, 9) . However, these other mutations had no effect on the kinetics of sodium stimulation of carnitine transport.
One of the natural mutations identified in this study, Y447C, abolished both carnitine and TEA transport (Fig. 2) . The mechanism for the complete lack of transport activity was found to be the defective maturation of the Y447C transporters to the plasma membrane, as assessed by confocal microscopy (Fig. 7) . By contrast, the carnitine transporters with the other substitutions evaluated in this study (Y447F, Y449D, Y449F, and Y454F) reached the plasma membrane normally (Fig. 8) . Mutations causing a defect in membrane insertion have been reported for other transporters such as the sodium-dependent glucose transporter SGLT1 (21) , but the Y447C substitution is the first mutation in OCTN2 that affects maturation to the plasma membrane. Several other missense mutations in OCTN2 result in complete loss of carnitine transport activity (4, 5) . These other mutations might have a similar basis for their lack of function.
The mechanism by which the domain comprising Y447, Y449, and E452 affects sodium stimulation of carnitine transport remains intriguing. The most accepted model of the OCTN2 transporter places the domain affected by these substitutions in an intracellular loop between transmembrane domains 10 and 11 (Fig. 4) . This model, although not experimentally confirmed, is supported by the homology of OCTN2 with other organic cation transporters (20) and the correct localization of conserved residues in these other transporters to the appropriate side of the membrane (22) . Previous studies have shown (11) that the E452K substitution impaired the sodium stimulation of carnitine transport probably by retarding the transfer of the sodium-carnitine complex across the plasma membrane. The Y449D and Y447F substitutions probably act similarly, because the K m toward carnitine remains unaffected (Fig. 5) . The domain affected by the Y447C, Y449D, and E452K substitutions is identical among carnitine transporters from different species (rat, mouse, and human) and is also extremely well conserved among different cation transporters (hOCT1, hOCT2, hOCT3, hOCTN1, and OCTN3). Because several of these transporters are sodium-independent, this domain must serve a fundamental role in the function of membrane transporters in general.
Recent structural studies on the bacterial lactose permease, a H ϩ -dependent sugar transporter, have identified transmembrane residues important for substrate recognition (23) . Binding of the cosubstrate (H ϩ ) and the substrate (lactose) is followed by a structural change favoring the transition of the transmembrane domains of the transporter from outward to inward facing (23) . The intracellular loops connecting different transmembrane domains seem to function as hinges around which the changes in conformation from outward to inward facing occur (23, 24) . Our data suggest that intracellular loops may play an active role in this transition, and substitutions in key residues might retard the transfer of the sodium-solute complex.
In summary, the domain between transmembrane regions 10 and 11 of OCTN2 comprises several residues affected by natural mutations. One of these (Y447C) impairs the maturation of the OCTN2 transporter to the plasma membrane. Two natural mutations, E452K (11) and Y449D, impair carnitine transport and decrease sodium stimulation of carnitine transport. The Y447F substitution had a similar effect on the sodium stimulation of carnitine transport, whereas Y449F and Y454F had no effect on sodium stimulation of carnitine transport. Y447F is the first conserved substitution of a tyrosine that impairs the sodium activation of substrate transfer in a sodium-solute cotransporter. However, the mechanism of sodium interaction with tyrosine residues might differ from that which is usually proposed (12) (13) (14) (15) in view of the putative intracellular localization of this tyrosine residue.
